We are set to treat myopia, digitally
Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision.
Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. It has grown to alarming proportions in Asia where prevalence rates, e.g., in Singapore, have reached 80% among young adults. High myopia imposes a significant risk to cause visual impairment and even blindness later in life.
The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. Additionally, the company is backed with venture capital in a seed round to advance the research and further develop the product for clinical validation.
Dr. Hamed Bahmani
Founder, Managing Director
Co-Founder, Managing Director
Hamed is the founder and managing director of Dopavision. He combines expertise in neuroscience, vision sciences, and engineering with an innovative mindset that drives Dopavision. He has years of experience in academia and industry, and is currently a visiting scholar at the Max Planck Institute for Biological Cybernetics.
Stefan is the co-founder and managing director of Dopavision. He’s an entrepreneur and a former strategy consultant, passionate about developing ideas that make consumers’ and patients’ lives better. He founded Cubitabo, an online retailer for bedroom furniture, and has previously worked at McKinsey&Company.
Yeshwanth is the product engineer working on devices to realize the myopia treatment. He has a background in physics from Jacobs University Bremen and worked for ZEISS Vision Science Lab in optics simulation and virtual reality. He is the swiss army knife of Dopavision working on different facets from hardware to research to software.
Tim is the vision scientist at Dopavision. He is interested in color, pupil and brain research in context of visual performance and myopia. He is fascinated by making the world more colorful. He has studied neuroscience as a PhD candidate at the ZEISS Vision Science Lab, Institute of Ophthalmic Research, University Clinic Tübingen and as a guest scientist at the Max Planck Institute for Biological Cybernetics.
Email : firstname.lastname@example.org